Small Molecules to Big Partnership: Incyte, Genesis Expand AI Collaboration to $1B+

Behind the expansion of their collaboration, Incyte and Genesis say, is the promise shown so far by the two initial targets, both selected by Incyte as called for in the initial strategic collaboration. One is a “very hard-to-drug, novel target” for which the companies worked to create novel, first-in-class chemical matter, while the other is a target that other companies have sought to make druggable without success, Pablo J. Cagnoni, MD, Incyte’s president and global head of R&D, told GEN.

The post Small Molecules to Big Partnership: Incyte, Genesis Expand AI Collaboration to $1B+ appeared first on GEN - Genetic Engineering and Biotechnology News.